Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Nafamostat
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : CorMedix
Deal Size : $5.0 million
Deal Type : Financing
CorMedix Announces Strategic Minority Investment in Talphera
Details : Talphera expects to use the proceeds of the equity financing to fund the completion of its ongoing Phase 3 registrational study for Niyad, a lyophilized formulation of nafamostat.
Product Name : Niyad
Product Type : Miscellaneous
Upfront Cash : Undisclosed
September 08, 2025
Lead Product(s) : Nafamostat
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : CorMedix
Deal Size : $5.0 million
Deal Type : Financing
Lead Product(s) : Nafamostat
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Talphera Enrolls First Patient in Trial for Nafamostat in Extracorporeal Circuit
Details : Talphera's lead product candidate, Niyad is a lyophilized formulation of nafamostat mesylate and is currently being studied under an IDE as an anticoagulant for the extracorporeal circuit.
Product Name : Niyad
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 19, 2024
Lead Product(s) : Nafamostat
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : XOMA
Deal Size : $8.0 million
Deal Type : Acquisition
XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition
Details : XOMA acquired an economic interest in DSUVIA® (sufentanil sublingual tablet), an opioid agonist, indicated for use in adults, for the management of acute pain, from Talphera.
Product Name : Dsuvia
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 18, 2024
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : XOMA
Deal Size : $8.0 million
Deal Type : Acquisition
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 26, 2016
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 25, 2016
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : U.S. Army Medical Research and Development Command
Deal Size : Inapplicable
Deal Type : Inapplicable
Open-Label Safety and Efficacy of the Sufentanil Sublingual Tablet 30 mcg for Acute Pain
Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 19, 2015
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : U.S. Army Medical Research and Development Command
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pain, Postoperative.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2015
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics of Sufentanil Sublingual Microtablet 30 mcg and 15 mcg in Healthy Subjects
Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 10, 2014
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Single and Multiple Dose Pharmacokinetics of Sufentanil NanoTab
Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 07, 2013
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics
Details : Sufentanil is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 04, 2012
Lead Product(s) : Sufentanil Citrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable